Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 gene

被引:77
|
作者
Innocenti, Federico [1 ,3 ,4 ]
Liu, Wanqing [1 ]
Fackenthal, Donna [2 ]
Ramirez, Jacqueline [1 ]
Chen, PeiXian [2 ]
Ye, Xin [1 ]
Wu, Xiaolin [2 ]
Zhang, Wei [1 ]
Mirkov, Snezana [1 ]
Das, Soma [2 ,3 ]
Cook, Edwin, Jr. [5 ]
Ratain, Mark J. [1 ,3 ,4 ]
机构
[1] Univ Chicago, Dept Med, Chicago, IL 60637 USA
[2] Univ Chicago, Dept Genet, Chicago, IL 60637 USA
[3] Univ Chicago, Comm Clin Pharmacol & Pharmacogenom, Chicago, IL 60637 USA
[4] Univ Chicago, Canc Res Ctr, Chicago, IL 60637 USA
[5] Univ Illinois, Dept Psychiat, Chicago, IL 60612 USA
来源
PHARMACOGENETICS AND GENOMICS | 2008年 / 18卷 / 08期
关键词
haplotype; pharmacogenetics; single nucleotide polymorphism; splicing variant; UDP-glucuronosyltransferase; 2B7;
D O I
10.1097/FPC.0b013e3283037fe4
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Objective UDP-glucuronosyltransferase 2B7 (UGT2B7) plays a central role in the liver-mediated biotransformation of endogenous and exogenous compounds. The genetic basis of interindividual variability in UGT2B7 function is unknown. This study aimed to discover novel gene variants of functional significance. Methods Caucasian human livers n=54) were used. UGT2B7 was resequenced in 12 samples [(six highest and six lowest for the formation of morphine-3-glucuronide (M3G)]. Haplotype-tagging single nucleotide polymorphisms were genotyped in the entire sample set. Samples were phenotyped for mRNA expression. Results 10 haplotype-tagging single nucleotide polymorphisms were identified and their haplotypes were inferred. Haplotype 4 (-45597G; -6682-6683A; 372A; IVS1 + 9_IVS1 + 10A; IVS1 + 829T; IVS1 + 985G; lVS1 + 999C; IVS1 + 1250G; 801 T; IVS4 + 185C) (frequency of 0.12) was associated with an increase in enzyme activity and gene expression. The 1/4 and 4/6 diplotypes had higher M3G formation compared with 1/1 (P<0.05) and 2/3 (P<0.01) diplotypes. Diplotypes containing haplotype 4 resulted in a significant 45% average increase in the formation of M3G compared with diplotypes without haplotype 4 (P=0.002). There was also an association between haplotype 4 and increased mRNA expression. lVS1 +985A>G, 735A>G, and 1062C>T are the putative functional variants of haplotype 4. We also identified two mRNA splicing variants (UGT2B7_v2 and UGT2B7_v3) splicing out exon 1, 4, 5, and 6 but sharing exons 2 and 3 with the involvement of additional 5' exons. UGT2B7_v2 was detected in all livers tested, but UGT2B7_v3 was present at much lower levels compared with UGT2B7_v2. The UGT2B7 reference sequence mRNA is now named UGT2B7_v. Conclusion UGT2B7 haplotype 4 is functional and its effects on the biotransformation of UGT2B7 substrates should be tested in controlled clinical trials. Biochemical studies should investigate the functional role of the newly discovered mRNA splicing variants.
引用
收藏
页码:683 / 697
页数:15
相关论文
共 50 条
  • [1] Human UDP-glucuronosyltransferase 2B7
    Radominska-Pandya, A
    Little, JM
    Czernik, PJ
    CURRENT DRUG METABOLISM, 2001, 2 (03) : 283 - 298
  • [2] SNP discovery and functional assessment of variation in the UDP-glucuronosyltransferase (UGT2B7) gene.
    Liu, W.
    Fackenthal, D.
    Ramirez, J.
    Chen, P.
    Ye, X.
    Wu, X.
    Zhang, W.
    Mirkov, S.
    Dast, S.
    Cook, E., Jr.
    Rataint, M. J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S79 - S79
  • [3] Polymorphisms and Haplotypes of the UDP-Glucuronosyltransferase 2B7 Gene Promoter
    Hu, Dong Gui
    Meech, Robyn
    Lu, Lu
    McKinnon, Ross A.
    Mackenzie, Peter I.
    DRUG METABOLISM AND DISPOSITION, 2014, 42 (05) : 854 - 862
  • [4] Genetic Polymorphism in UDP-Glucuronosyltransferase 2B7 and Colorectal Cancer Risk
    van der Logt, E. M. J.
    te Morsche, R. H. M.
    Groenendaal, N.
    Roelofs, H. M. J.
    de Metz, M.
    van der Stappen, J. W.
    Nagengast, F. M.
    Peters, W. H. M.
    ONCOLOGY RESEARCH, 2008, 17 (07) : 323 - 329
  • [5] Glucosidation of hyodeoxycholic acid by UDP-glucuronosyltransferase 2B7
    Mackenzie, P
    Little, JM
    Radominska-Pandya, A
    BIOCHEMICAL PHARMACOLOGY, 2003, 65 (03) : 417 - 421
  • [6] The aglycone binding site of UDP-glucuronosyltransferase 2B7
    Coffman, BL
    Kearney, WR
    Goldsmith, S
    Knosp, BM
    Tephly, TR
    FASEB JOURNAL, 2003, 17 (04): : A608 - A608
  • [7] Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7
    Innocenti, F
    Iyer, L
    Ramírez, J
    Green, MD
    Ratain, MJ
    DRUG METABOLISM AND DISPOSITION, 2001, 29 (05) : 686 - 692
  • [8] Heterodimerization of Human UDP-Glucuronosyltransferase 1A9 and UDP-Glucuronosyltransferase 2B7 Alters Their Glucuronidation Activities
    Xue, Jia
    Yin, Jiayi
    Nie, Jing
    Jiang, Huidi
    Zhang, Haitao
    Zeng, Su
    DRUG METABOLISM AND DISPOSITION, 2023, 51 (11) : 1499 - 1507
  • [9] Genetic Variations in UDP-glucuronosyltransferase 2B7 Gene (UGT2B7) in a Korean Population
    Hwang, Mi-Sun
    Lee, Su-Jun
    Jeong, Hye-Eun
    Lee, SangSeop
    Yoo, Mi-Ae
    Shin, Jae-Gook
    DRUG METABOLISM AND PHARMACOKINETICS, 2010, 25 (04) : 398 - 402
  • [10] Inhibitory Effect of Sauchinone on UDP-Glucuronosyltransferase (UGT) 2B7 Activity
    You, Byoung Hoon
    Gong, Eun Chae
    Choi, Young Hee
    MOLECULES, 2018, 23 (02):